Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
出版年份 2023 全文链接
标题
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 20, Issue 10, Pages 664-677
出版商
Springer Science and Business Media LLC
发表日期
2023-07-24
DOI
10.1038/s41571-023-00794-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
- (2023) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.
- (2023) Clemens Aigner et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.
- (2023) Jonathan Spicer et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study.
- (2023) Shun Lu et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).
- (2023) Keiju Aokage et al. JOURNAL OF CLINICAL ONCOLOGY
- 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
- (2023) D.P. Carbone et al. Journal of Thoracic Oncology
- 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
- (2023) P.M. Forde et al. Journal of Thoracic Oncology
- Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
- (2023) Tina Cascone et al. NATURE MEDICINE
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
- (2023) Sapna P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
- (2023) Heather Wakelee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
- (2023) Masahiro Tsuboi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
- (2023) Mariano Provencio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-small-cell Lung Cancer
- (2022) Peng Zhang et al. ANNALS OF THORACIC SURGERY
- First-Line Immunotherapy for Non–Small-Cell Lung Cancer
- (2022) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2022) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
- (2022) Howard Jack West et al. Journal for ImmunoTherapy of Cancer
- VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
- (2022) L. Paz-Ares et al. ANNALS OF ONCOLOGY
- Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC
- (2022) Fan Zhang et al. Journal of Thoracic Oncology
- Perioperative targeted therapy for oncogene-driven NSCLC
- (2022) Si-Yang Liu et al. LUNG CANCER
- Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
- (2022) Edward S. Kim et al. NATURE MEDICINE
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- (2022) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
- (2022) Jia-Tao Zhang et al. Cancer Discovery
- Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
- (2022) Kenneth L. Kehl et al. JAMA Oncology
- Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
- (2022) Hiroaki Akamatsu et al. CLINICAL CANCER RESEARCH
- EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
- (2022) Mary E.R. O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.
- (2022) Fuming Qiu et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.
- (2022) Samuel Rosner et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
- (2022) Mariano Provencio et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
- (2022) Karen L. Reckamp et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
- (2022) Jeanne Tie et al. NEW ENGLAND JOURNAL OF MEDICINE
- 972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial
- (2022) G. Zalcman et al. ANNALS OF ONCOLOGY
- LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
- (2022) E.B. Garon et al. ANNALS OF ONCOLOGY
- Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227
- (2022) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical Results of the Lung Cancer Mutation Consortium 3 (LCMC 3) Trial:
- (2022) Valerie W. Rusch et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
- (2022) H. Wakelee et al. Journal of Thoracic Oncology
- OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
- (2022) D. Rodriguez-Abreu et al. Journal of Thoracic Oncology
- Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
- (2022) Jamie E. Chaft et al. NATURE MEDICINE
- Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
- (2022) Marie Wislez et al. Journal for ImmunoTherapy of Cancer
- LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)
- (2022) T.S.K. Mok et al. ANNALS OF ONCOLOGY
- Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma
- (2022) Bharathi Muthusamy et al. Journal of Thoracic Oncology
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
- (2021) Ahmet Sezer et al. LANCET
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
- (2021) Nasser K Altorki et al. LANCET ONCOLOGY
- Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
- (2021) Jamie E. Chaft et al. Nature Reviews Clinical Oncology
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
- (2021) E. Felip et al. ANNALS OF ONCOLOGY
- Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges
- (2021) Xabier Mielgo-Rubio et al. Future Oncology
- SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
- (2021) Sacha I. Rothschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study.
- (2021) Sanja Dacic et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
- (2021) Dean F. Bajorin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer
- (2021) Toon Allaeys et al. Cancers
- 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
- (2021) C. Zhou et al. ANNALS OF ONCOLOGY
- 1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC
- (2021) M.G. Kris et al. ANNALS OF ONCOLOGY
- Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)
- (2021) Liang Xia et al. CLINICAL CANCER RESEARCH
- Surgery without preoperative histological confirmation of lung cancer: what is the current clinical practice?
- (2021) Mohammad R. Ghamati et al. Journal of Thoracic Disease
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
- (2020) Shugeng Gao et al. Journal of Thoracic Oncology
- Harnessing cancer immunotherapy during the unexploited immediate perioperative period
- (2020) Pini Matzner et al. Nature Reviews Clinical Oncology
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
- (2020) Catherine A Shu et al. LANCET ONCOLOGY
- Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model
- (2020) Asunción Martín-Ruiz et al. Scientific Reports
- 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
- (2020) B. Besse et al. ANNALS OF ONCOLOGY
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
- (2020) Barzin Y. Nabet et al. CELL
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
- (2020) David M. Waterhouse et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
- (2020) Siddharth Sheth et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
- (2020) Joshua E Reuss et al. Journal for ImmunoTherapy of Cancer
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Current status of immune checkpoint inhibition in early-stage NSCLC
- (2019) J Vansteenkiste et al. ANNALS OF ONCOLOGY
- Perioperative dynamic changes in circulating tumor DNA in lung cancer patients (DYNAMIC)
- (2019) Kezhong Chen et al. CLINICAL CANCER RESEARCH
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer
- (2018) Tina Cascone et al. CANCER RESEARCH
- Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity
- (2018) Orneala Bakos et al. Journal for ImmunoTherapy of Cancer
- Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer
- (2018) Valsamo Anagnostou et al. CANCER RESEARCH
- Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
- (2018) Matthew J. Bott et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non–Small-Cell Lung Cancer
- (2013) Wei-Yu Liao et al. Clinical Lung Cancer
- Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials
- (2012) Guillaume Mouillet et al. Journal of Thoracic Oncology
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
- (2010) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation